Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR-17 Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Research and development
      • XR-18
      • XR-19
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • Key value drivers
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Press releases

All releases
  • Regulatory Releases
  • Press Releases
2021
  • 2023
  • 2022
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • All years
Non Regulatory
December 10, 2021

Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea®

Regulatory
December 2, 2021

Nomination Committee appointed for the 2022 Annual General Meeting in Oasmia

Non Regulatory
November 26, 2021

Oasmia to present at Stora Aktiedagen Stockholm on December 2

Non Regulatory
November 26, 2021

Oasmia to present at the Erik Penser Bank Life Science Day on December 2

Regulatory
November 18, 2021

Interim report for the period January 1, 2021 – September 30, 2021

Non Regulatory
November 11, 2021

Invitation to presentation of Oasmia’s Q3 report on November 18

Regulatory
October 21, 2021

Oasmia announces global settlement of all disputes with MGC Capital, former Board Members of Oasmia and members of former management

Non Regulatory
October 20, 2021

Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory
September 24, 2021

Oasmia to present at Naventus Life Science Summit on September 29

Regulatory
September 20, 2021

Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB

Non Regulatory
September 17, 2021

Oasmia signs agreement with FarmaMondo to commercialize Paclical® in Russia & CIS

Non Regulatory
August 31, 2021

Oasmia to present at Aktiedagen Stockholm on September 7

Non Regulatory
August 26, 2021

Oasmia strengthens internal capabilities with the appointments of Head of Clinical Development & Head of Regulatory Affairs

Regulatory
August 19, 2021

Interim report for the period January 1, 2021 – June 30, 2021

Non Regulatory
August 10, 2021

Invitation to presentation of Oasmia’s Q2 report on August 19

Non Regulatory
June 30, 2021

Cantrixil positive Phase I trial data published in the journal Cancers

Non Regulatory
June 28, 2021

Oasmia transfers Nordic commercialization rights for Apealea® to Inceptua

Non Regulatory
June 10, 2021

First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

Non Regulatory
June 9, 2021

Oasmia Provides a R&D Update on its Technology Platforms

Non Regulatory
June 2, 2021

Oasmia to present at Aktiespararna’s Småbolagsdagar on June 9

Regulatory
May 27, 2021

Report from Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory
May 27, 2021

Interim report for the period January 1, 2021 – March 31, 2021

Regulatory
April 29, 2021

Oasmia publishes Annual Report for 2020

Regulatory
April 27, 2021

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

Regulatory
April 27, 2021

The Nomination Committee of Oasmia proposes Andrea Buscaglia as new Board member

Non Regulatory
April 21, 2021

Phase 1b Trial of Oasmia’s Docetaxel Micellar in Advanced Prostate Cancer is Granted Ethical Committee Approval and can be Initiated

Non Regulatory
April 12, 2021

Oasmia Presents Cantrixil Final Phase I Data at the 2021 AACR Annual Meeting

Non Regulatory
April 1, 2021

Oasmia Pharmaceutical Appoints Dr Reinhard Koenig as Chief Scientific Officer

Non Regulatory
March 26, 2021

Oasmia to Present Cantrixil Final Phase I Data at the 2021 AACR Virtual Annual Meeting

Regulatory
March 24, 2021

Oasmia wins sole rights to record patents in its own name and is awarded full legal costs

Non Regulatory
March 24, 2021

European Patent Office Informs Oasmia of its Intention to Grant XMeNa Patent

Non Regulatory
March 3, 2021

Oasmia and Karolinska Institutet to collaborate on the biological potential of Oasmia’s proprietary drug delivery platform

Regulatory
March 1, 2021

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Regulatory
February 19, 2021

Year-end report[1] for the shortened[2] financial year May 1, 2020 – December 31, 2020

Non Regulatory
February 16, 2021

Invitation to presentation of Oasmia’s Year-end report on February 19

Non Regulatory
January 29, 2021

Oasmia Pharmaceutical Appoints Dr. Heidi B. Ramstad as Chief Medical Officer

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Media
    • Press releases
    • Presentations
    • Events
    • Subscribe
    • Image Bank
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com